Clinical research studies, or clinical trials, help scientists and doctors evaluate the safety and potential anti-cancer activity of new medical treatments. The study may take place at a hospital, clinic, university, or doctor’s office.

Boundless Bio, a biopharmaceutical company, is sponsoring the study, which is being conducted by cancer doctors (or oncologists) at the clinical study sites.

Investigational means that the therapy has not been approved for medical use and is currently being studied to understand its safety and potential anti-cancer activity. Studies of investigational therapies may only be performed with the permission of, and under the oversight of, the regulatory authority of the country where the study is being conducted, such as the US Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. BBI-355 is an investigational therapy not yet approved by the FDA or EMA.  

This type of information about your cancer is called genomic information.  To understand the genomic information about your cancer, a sample of your tumor, or sometimes a sample of your blood, will be tested for the presence of CCNE1, MYC, KRAS, and other genomic biomarkers.  This type of testing is called next-generation sequencing, or ‘NGS’ testing. Ask your cancer doctor about your next-generation sequencing (NGS) report.  NGS testing and the resulting NGS report may have been done by any of these, or other, testing companies – Foundation Medicine, Tempus, Guardant, or Caris, and will contain genomic information about your cancer, including whether you have CCNE1, MYC, KRAS, or another gene amplified in your cancer.

Typically, on the first or second page of the report you will see a list of genes in “Genomic Findings” or “Genomic Variants” or “Molecular Findings”.  On this list, you may see genes with “amplification” or “copy number gain”.  If your report includes CCNE1, MYC, KRAS, or other genes with amplification or copy number gain, you may be eligible for the study.

Click here to see where to look on your NGS report >>

Speak to your cancer doctor about genomic testing of your cancer.

The oncology care team at the clinical study site will explain in detail to you what participation in the POTENTIATE study means for you.  Participation is completely voluntary, and you are permitted to change your mind about participation at any time.

 People choosing to participate will be asked to do the following:

• Attend visits and have assessments such as blood draws to find out if you qualify for the study.

• Take the investigational therapy as directed by the study doctor.

• Participate in follow up appointments including additional blood draws and tumor imaging (scans).

The length of time you will be in the study depends on how your body responds to the therapy.  You will always have the option to stop at any time.

You or your cancer doctor can contact a study Investigator or the study coordinator at any of the clinical study sites participating in the conduct of the POTENTIATE study. 

See Site Map >>

Your primary care physician or cancer doctor may be able to refer you to one of the clinical study sites. Travel support may be available to help you travel to one of the clinical study sites.

Additional sites may be opening, so keep checking back for updates.